Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a leading global pharmaceutical company headquartered in Bridgewater, NJ. Amneal develops, manufactures, and distributes a diverse portfolio of over 280 generic and specialty pharmaceutical products across the United States, India, and Ireland. With a commitment to providing affordable medicines, Amneal operates through three key segments: Generics, Specialty, and AvKARE.
Generics Segment: This segment focuses on producing a wide range of dosage forms and delivery systems, including injectables and biosimilars, contributing significantly to the company's revenue. The Generics segment is dedicated to expanding across complex product categories and therapeutic areas, ensuring patients have access to vital medications.
Specialty Segment: Amneal's Specialty segment promotes proprietary branded pharmaceuticals targeting central nervous system and endocrine disorders. The segment has a growing portfolio of branded pharmaceuticals with a pipeline focused on addressing unmet medical needs, demonstrating the company's commitment to innovation.
AvKARE Segment: This segment distributes pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution. AvKARE focuses on offering consistent care and pricing to qualified entities, enhancing access to essential medicines for governmental and institutional markets.
Recently, Amneal has achieved significant milestones, including the resubmission of a Complete Response to the FDA for IPX203, an oral formulation for Parkinson’s disease, and entering a licensing agreement with Zambon Biotech for IPX203 in Europe. The company also launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, underscoring their commitment to oncology treatment advancements.
Amneal's financial performance remains robust, with net revenue of $2.39 billion in 2023 and a strategic focus on expanding its reach through innovative products and international partnerships. The company continuously invests in research and development to meet the growing demands for affordable and high-quality medications, solidifying its position as a key player in the pharmaceutical industry. For more information, please visit www.amneal.com.
Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in two upcoming investor conferences: the Raymond James Institutional Investors Conference on March 1, 2021, at 3:00 p.m. ET, and the Barclays Global Healthcare Conference on March 10, 2021, at 4:10 p.m. ET. Both events will include fireside chats and can be accessed via a live webcast on the Company's Investor Relations website. Amneal focuses on developing and distributing generic and specialty pharmaceuticals, boasting around 250 product families, and operates globally, including a majority stake in AvKARE, which supplies pharmaceuticals to government agencies.
Amneal Pharmaceuticals (NYSE: AMRX) is set to release its fourth quarter and full year 2020 financial results on February 26, 2021, before market open. A conference call and live webcast will take place at 8:30 a.m. ET that day, accessible via the Investor Relations section of Amneal's website. Participants can join by dialing (844) 746-0741 in the U.S. or (412) 317-5273 internationally. A replay will be available for seven days at (877) 344-7529 for U.S. callers and (412) 317-0088 for international callers, using access code 10152029.
Amneal Pharmaceuticals (NYSE:AMRX) has announced a definitive agreement to acquire a 98% interest in Kashiv Specialty Pharmaceuticals, enhancing its growth strategy. The $70 million upfront payment, plus $30 million after a year and potential contingent payments of $8 million, aims to boost Amneal's pipeline in neurology and endocrinology. This acquisition is expected to deliver approximately $15 million in annual adjusted EBITDA. The deal strengthens Amneal's R&D capabilities and is expected to close in Q2 2021, subject to regulatory approval.
Amneal Pharmaceuticals (NYSE: AMRX) announced FDA approval for a 500 mg strength of its Abiraterone Acetate Tablets, a generic version of Zytiga® for metastatic prostate cancer. This approval follows the existing 250 mg strength and allows for use in combination with Prednisone. Amneal has initiated commercialization for this additional strength, which could tap into the U.S. market valued at approximately $413 million annually, as reported by IQVIA™.
Amneal Pharmaceuticals (NYSE: AMRX) announced that Co-CEO Chirag Patel will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 PM ET. The presentation will be available via a live webcast on the Company's Investor Relations website, with a replay accessible for 30 days afterward. Amneal is a fully-integrated pharmaceutical company with a diverse portfolio of approximately 250 product families, focusing on generic and specialty drug products. The Company also owns 65% of AvKARE, which serves various governmental agencies.
Amneal Pharmaceuticals (NYSE: AMRX) has received FDA approval for its Acyclovir Cream, 5%, a generic version of Zovirax® for treating recurrent cold sores in adults and adolescents. This product, which is available by prescription, is a noteworthy addition to Amneal's portfolio, representing a significant step in its strategy to provide accessible complex generics. The U.S. annual sales for Acyclovir Cream for the year ending September 2020 were around $67 million, highlighting its market potential.
Amneal Pharmaceuticals (NYSE: AMRX) reported a strong third quarter for 2020, with net revenue of $519 million, a 37% increase compared to $378 million in Q3 2019. This growth was driven by the AvKARE acquisition and new product launches, partially offset by competition in some segments. The net loss improved to $9 million from $265 million year-over-year, while diluted loss per share decreased to $0.06 from $2.03. Adjusted EBITDA surged to $114 million, a 60% rise, and the company updated its full-year guidance, projecting net revenue of $1.95 billion - $2 billion.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its third quarter 2020 financial results on November 6, 2020, before market open. A conference call and live webcast will follow at 8:30 a.m. ET, accessible via the Investor Relations section on their website. For those unable to attend live, a replay will be available for seven days post-call. Amneal is a fully-integrated pharmaceutical company with a diverse portfolio of around 250 product families, focusing on generic and specialty drugs across North America, Asia, and Europe.
Amneal Pharmaceuticals (NYSE: AMRX), based in Bridgewater, NJ, is a fully-integrated pharmaceutical company engaged in developing, manufacturing, and distributing generic and specialty drugs. With a portfolio of around 250 product families, the company also focuses on complex dosage forms and branded products in central nervous system and endocrine disorders. Owning 65% of AvKARE, Amneal primarily serves governmental agencies, including the Department of Defense and Veterans Affairs. The company is expanding its reach across North America, Asia, and Europe to deliver high-quality medicines.
Amneal Pharmaceuticals (NYSE: AMRX) and PL Developments have begun shipping store brand equivalent Voltaren® Arthritis Pain Gel (diclofenac sodium topical gel, 1%) in various sizes after receiving FDA clearance. This product, previously available only by prescription, is significant for US consumers. The original Voltaren® Arthritis Pain generated approximately $250 million in sales prior to its switch to OTC in February 2020. This collaboration aims to enhance the availability of affordable generic medicines, demonstrating Amneal's commitment to accessible healthcare.
FAQ
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
What is the market cap of Amneal Pharmaceuticals (AMRX)?
What does Amneal Pharmaceuticals, Inc. specialize in?
What are the key segments of Amneal Pharmaceuticals?
Where is Amneal Pharmaceuticals headquartered?
What recent product has Amneal Pharmaceuticals launched in the oncology space?
What is the significance of Amneal's IPX203?
How does Amneal Pharmaceuticals contribute to the U.S. pharmaceutical market?
What financial performance did Amneal achieve in 2023?
How is Amneal addressing the opioid crisis?
What are some key partnerships of Amneal Pharmaceuticals?
How can investors get more information about Amneal Pharmaceuticals?
